A 10-year prospective surveillance of Mycobacterium tuberculosis drug resistance in France 1995-2004

European Respiratory Journal

Volumn 30, Issue 5, 2007, Pages 937-944

  Khue P M ^a,b   Truffot Pernot, C ^a,b   Texier Maugein, J ^c   Jarlier, V ^a,b   Robert, J ^a,b  

^a SORBONNE UNIVERSITÉ   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Isoniazid; Resistance; Rifampicin; Surveillance; Trend; Tuberculosis

Indexed keywords

ETHAMBUTOL; ISONIAZID; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; PRIORITY JOURNAL; RISK FACTOR; TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, BACTERIAL; FEMALE; FRANCE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PROSPECTIVE STUDIES; SENTINEL SURVEILLANCE; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 38849136650     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.00037207     Document Type: Article

References (19)

1. WHO/IUATLD. Antituberculosis drug resistance in the world. Report No 2, prevalence and trends. The WHO/IUATLD global project on anti-tuberculosis drug resistance surveillance. Geneva, World Health Organization, 2000. Report No.: WHO/CDS/TB/2000.278.
2. WHO/IUATLD. Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis 1998; 2: 72-89.
3. Schwoebel V, ML Moro, CS Lambregts-van Weezenbeek et al. Standardisation of antituberculosis drug resistance surveillance in Europe. Recommendations of a World Health Organization (WHO) and International Union Against Tuberculosis and Lung Disease (IUALD) Working Group. Eur Respir J 2000; 16: 364-371.
4. Che D. Les cas de tuberculose déclarés en France en 2004. [Tuberculosis cases notified in France 2004.] Bull Epidemiol Hebdo 2006; 18: 121-125.
5. Canetti G, Gay P, Le Lirzin M. Trends in the prevalence of primary drug resistance in pulmonary tuberculosis in France from 1962 to 1970: a national survey. Tubercle 1972; 53: 57-83.
6. Robert J, Trystram D, Truffot-Pernot C, Carbonnelle B, Grosset J, AZAY Mycobacteria Study Group. Surveillance of Mycobacterium tuberculosis drug resistance in France, 1995-1997. Int J Tuberc Lung Dis 2000; 4: 665-672.
7. World Health Organization. Guidelines for Surveillance of Drug Resistance in tuberculosis. 2nd Edn. Geneva, WHO, 2003. 8 Heifets L. Susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. J Med Microbiol 2002; 51: 11-12.
8. Borgdorff MW, van der Werf MJ, de Haas PE, Kremer K, van Soolingen D. Tuberculosis elimination in the Netherlands. Emerg Infect Dis 2005; 11: 597-602.
9. Aziz MA, Wright A, Laszlo A, et al. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 2006; 368: 2142-2154.
10. EuroTB and the national coordinators for tuberculosis surveillance in the WHO European region. Surveillance of tuberculosis in Europe. Report on tuberculosis case notified in 2004. Institut de Veille Sanitaire, Saint Maurice, 2006. www.eurotb.org/rapports/2004.pdf. Date last accessed August 8, 2007.
11. Crofton J, Chaulet P, Maher D. Guidelines for the management of drug resistant tuberculosis 1997. WHO/TB/96.210. www.who.int/gtb/publications/gmdrt/ index.htm Date last accessed: August 8, 2007.
12. Bauer J, Yang Z, Poulsen S, Andersen AB. Results from 5 years of nationwide DNA fingerprinting of Mycobacterium tuberculosis complex isolates in a country with a low incidence of M. tuberculosis infection. J Clin Microbiol 1998; 36: 305-308.
13. Lambregts-van Weezenbeek CSB, Jansen HM, Veen J, Nagelkerke NJD, Sebek MMGG, van Soolingen D. Origin and management of primary and acquired drug-resistant tuberculosis in The Netherlands: the truth behind the rates. Int J Tuberc Lung Dis 1998; 2: 296-302.
14. Ridzon R, Whitney CG, McKenna MT, et al. Risk factors for rifampin mono-resistant tuberculosis. Am J Respir Crit Care Med 1998; 157: 1881-1884.
15. Munsiff SS, Joseph S, Ebrahimzadeh A, Frieden TR. Rifampin-monoresistant tuberculosis in New York city, 1993-1994. Clin Infect Dis 1997; 25: 1465-1467.
16. Brossier F, Veziris N, Truffot-Pernot C, Jarlier V, Sougakoff W. Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance. J Clin Microbiol 2006; 44: 3659-3664.
17. Cailhol J, Che D, Campese C, Decludt B. Les cas de tuberculose déclarés enFrance en2001. [Tuberculosis cases notified in France 2001.] Bull Epidemiol Hebdo 2003; 10-11: 54-57.
18. Antoine D, Che D. Les cas de tuberculose déclarés en France en 2005. [Tuberculosis cases notified in France 2005.] Bull Epidemiol Hebdo 2007; 11: 85-89.
19. Guerrin-Tran E, Thiolet JM, Rousseau C, et al. An evaluation of data quality in a network for surveillance of Mycobacterium tuberculosis resistance to antituberculosis drugs in Ile-de-France region-2001-2002. Eur J Epidemiol 2006; 21: 783-785.